Uso de mifepristona para o tratamento de meningiomas irressecáveis: revisão sistemática e metanálise

Marcelo José da Silva de Magalhães; Nathalia Cristina Freitas  Souza; Heick Damasceno Batista

doi:10.47822/bn.v14i1.1121

Autores

Marcelo José da Silva de Magalhães Centro Universitário do Norte de Minas, Montes Claros, MG, Brasil https://orcid.org/0000-0002-8446-8684
Nathalia Cristina Freitas Souza Centro Universitário do Norte de Minas, Montes Claros, MG, Brasil
Heick Damasceno Batista Centro Universitário do Norte de Minas, Montes Claros, MG, Brasil https://orcid.org/0009-0001-0833-7121

DOI:

https://doi.org/10.47822/bn.v14i1.1121

Palavras-chave:

Meningioma. Mifepristona. Mifepristona. RU-486.

Resumo

Objetivo: realizar uma revisão sistemática e metanálise sobre o tratamento de meningiomas irressecáveis por meio do uso de mifepristona (RU-486). Materiais e Métodos: os descritores da busca foram Meningiomas,Hormonal treatment, Mifepristone, Progesterone antagonist, Unresectable tumors, Systematic review, Meta-analysis, Central Nervous System neoplasms, Clinical efficacy, Endocrine therapy. A data da busca foi 30/03/2024. As plataformas escolhidas para a pesquisa foram PubMed, Medline e Cochrane. A qualidade dos trabalhos incluídos foi avaliada pelas ferramentas Qualis e JBI. O trabalho foi registrado no PROSPERO-International prospective register of systematic reviews com o número: CRD42024550741. Resultados: após análise dos resultados, restaram 5 estudos elegíveis para esta revisão sistemática e metanálise, apenas um deles na fase III. Os trabalhos avaliaram um total de 219 pacientes portadores de meningiomas irressecáveis, dos quais 135 foram inicialmente destinados a receber mifepristona. Todos os trabalhos encontrados estudaram a posologia diária de 200 mg. A metanálise revelou que 58% dos pacientes tratados apresentaram pelo menos manutenção ou redução do volume tumoral nos exames de imagem, como tomografia e ressonância magnética do crânio, com significância estatística. Conclusão: a mifepristona parece promissora em pacientes do sexo masculino e feminino em idade fértil. Frente ao esgotamento das opções terapêuticas, é razoável considerar o tratamento com mifepristona.

Referências

Ogasawara C, Philbrick B, Adamson DC. Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. Biomedicines. 2021 Mar 21;9(3):319. Available from: https://doi.org/10.3390/biomedicines9030319

Louis ED, Mayer SA, Rowland LP. Merritt Tratado de Neurologia. 13th ed. Rio de Janeiro: Guanabara Koogan LTDA; 2018.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al.The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007 Aug;114(2):97-109. Available from: https://doi.org/10.1007/s00401-007-0243-4

Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996 Sep;39(3):197-205. Avaliable from: https://doi.org/10.1007/BF00165649

Cahil DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducker TB. Estrogen and progesterone receptors in meningiomas. J Neurosurg. 1984 May;60(5):985-993. Available from: https://doi.org/10.3171/jns.1984.60.5.0985

Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relationto pregnancy and menstruation. J Neurol Neurosurg Psychiatry. 1958 May;21(2):89-91. Available from: https://doi.org/10.1136/jnnp.21.2.89

Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003 Dec;68(6):409-420. Available from: https://doi.org/10.1016/S0010-7824(03)00171-9

Baulieu EE. Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor. Science. 1989 Sep 22;245(4919):1351-1357. https://doi.org/10.1126/science.2781282

Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T.Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg. 1994 Mar;80(3):527-534. Available from: https://doi.org/10.3171/jns.1994.80.3.0527

Olson JJ, Beck DW, Schlechte JA, Loh PM. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg. 1987 Apr;66(4):584-587. Available from: https://doi.org/10.3171/jns.1987.66.4.0584

Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991 Nov;74(6):861-866. Available from: https://doi.org/10.3171/jns.1991.74.6.0861

Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JWet al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry. 1992 Jun 1;55(6):486-490. Available from: https://doi.org/10.1136/jnnp.55.6.486

Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Dec;24(8):727-733. Available from: https://doi.org/10.1080/07357900601062339

Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, et al. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol. 2015 Dec;33(35):4093-4098. Available from: https://doi.org/10.1200/JCO.2015.61.6490

- Touat M, Lombardi G, Farina P, Michel Kalamarides M, Sanson M. Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir.2014;156:1831–1835.Available from: https://doi.org/10.1007/s00701-014-2188-4

Jhawar BS, FuchsCS, Colditz GA, Stampfe MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003 Nov;99(5):848-853. Available from: https://doi.org/10.3171/jns.2003.99.5.0848

Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology. 1975 Aug;28(8):705-712. Available form: https://doi.org/10.1212/WNL.25.8.705

Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD. Epidemiology of intracranial meningioma. Cancer. 1993 Aug 1;72(3):639-48. Available from: https://doi.org/10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P

Wahab M, Al-Azzawi F. Meningioma and hormonal influences. Climacteric. 2003 Dec;6(4):285-92. Available from: https://pubmed.ncbi.nlm.nih.gov/15006250/

Koper JW, Foekens JA, Braakman R, Lamberts SW. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res. 1990 May 1;50(9):2604-7. Available from: https://pubmed.ncbi.nlm.nih.gov/2183929/

Nasrallah MP, Aldape KD. Molecular classification and grading of meningioma. J Neurooncol. 2023 Jan;161(2):373-381. Available from: https://doi.org/10.1007/s11060-022-04228-9

Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, et al. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. J Clin Oncol. 2021 Dec 1;39(34):3839-3852. Available from: https://doi.org/10.1200/JCO.21.00784

Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol. 2018 Sep;14(21):2161-2177. Available from: https://doi.org/10.2217/fon-2018-0006

Spitz IM, Grunberg SM, Chabbert-Buff N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. FertilSteril. 2005 Dec;84(6):1561-1844. Available from: https://doi.org/10.1016/j.fertnstert.2005.05.056

Uso de mifepristona para o tratamento de meningiomas irressecáveis

revisão sistemática e metanálise

Autores

DOI:

Palavras-chave:

Resumo

Referências

Downloads

Publicado

Como Citar

Edição

Seção

Licença